<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel rdf:about="http://hdl.handle.net/10366/132636">
<title>GMO. Monografías</title>
<link>http://hdl.handle.net/10366/132636</link>
<description/>
<items>
<rdf:Seq>
<rdf:li rdf:resource="http://hdl.handle.net/10366/138242"/>
</rdf:Seq>
</items>
<dc:date>2026-05-04T18:05:59Z</dc:date>
</channel>
<item rdf:about="http://hdl.handle.net/10366/138242">
<title>CRISPR-ERA for switching off (onco)genes</title>
<link>http://hdl.handle.net/10366/138242</link>
<description>[EN]Genome editing nucleases like the popular CRISPR/Cas9 allow generate knock&#13;
-&#13;
out cell lines and nulls zygotes &#13;
by inducing site&#13;
-&#13;
specific DSB within a genome. In most cases, when a DNA template is not present, the DSB is &#13;
repaired by &#13;
non&#13;
-&#13;
homologous&#13;
end joining (NHEJ) resulting in small nucleotide insertions or deletions that can &#13;
be  used  to  construct  knockout  alleles.  However,  for  se&#13;
veral  reasons,  these  mutations  do  not  produce  the &#13;
desired  null  result  in  all  cases,  generating  a  similar  protein  with  functional  activity.  That  undesirable  effect &#13;
could limit the therapeutic efficiency of gene therapy strategies focused on abrogating oncog&#13;
ene expression by &#13;
CRISPR/Cas9  and  should  be  taken  in  account.  This  chapter  reviews  the  irruption  of  CRISPR  technology  for &#13;
gene silencing and its application in gene therapy.
</description>
<dc:date>2018-01-01T00:00:00Z</dc:date>
</item>
</rdf:RDF>
